BioVie, an early stage biotech developing therapies for cirrhosis, filed on Tuesday with the SEC to raise up to $23 million in a Nasdaq uplisting. The company is currently listed on the OTCQB under the ticker BIVI.
The Los Angeles, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol BIVI. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
